COMPARING MOLECULAR EFFECTS OF VARIOUS CYTOPROTECTORS IN COMPLEX THERAPY OF CORONARY HEART DISEASE
Abstract
The molecular effects of trimetazidine and mildronate were investigated in patients with stable effort angina, Functional Class (FC) I-III. The comparison criteria included blood activity and concentrations of the main products of free-radical oxidation and the components of Krebs cycle and anti-oxidant system. Proteomic methods were also used. Trimetazidine and mildronate could be recommended as cardio-protectors in primary and secondary prevention of FC I-III coronary heart disease.
About the Author
E. A. Kartashova
Ростовский государственный медицинский университет, Ростов-на-Дону
Russian Federation
Russian Federation
References
1. Беленков Ю.Н. Хроническая сердечная недостаточность в России – опыт 25 лет: где мы находимся и куда должны идти? // Сердечная недостаточность. – 2003. -Т.4. – №1(17). – С.9- 11.
2. Гордеев И.Г., Бекчиу Е.А., Люсов, В.А. и др. Оценка влияния миокардиальных цитопротекторов на процессы перекисного окисления липидов у больных стабильной стенокардией до и после хирургической реваскуляризации миокарда // Российский кардиологический журнал. – 2005 – № 3. – С. 41 – 47.
3. Сарвилина И.В., Каркищенко В.Н., Горшкова Ю.В. Междисциплинарные исследования в медицине. – М.: Изд. “Техносфера”, 2007. – 368 с.
4. Маколкин В.И., Глезер М.Г, Жарова А.И. Ишемия миокарда: от понимания механизмов к адекватному лечению // Кардиология. – 2000. – Т. 40, № 9.
5. Калвиньш, И.Я. Милдронат и триметазидин: сходство и различие // Теrra Medica Nova. – 2002. – № 2. – С. 3-5.
6. Berger P. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries: results from the Multicenter American Research Trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MARCATOR) // J. Am. Coll. Cardiol. – 1996. – №27. – P.1-7.
7. Cashin-Hemphill L. Dinsmore R. et al. Atherosclerosis progression in subjects with and without post-angioplasty restenosis in QUIET // J. Am. Coll. Cardiol. – 1997. – № 29. – P.418.
8. Cooke G., Liu-Stratton A. Ferketich M. et al. The FRISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease // Lancet. – 1990. – № 336. – P. 827-830.
Review
For citations:
Kartashova E.A. COMPARING MOLECULAR EFFECTS OF VARIOUS CYTOPROTECTORS IN COMPLEX THERAPY OF CORONARY HEART DISEASE. Russian Journal of Cardiology. 2009;(5):62-67. (In Russ.)
Views:
657
Email this article 